TWD 38.75
(-1.77%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 893.84 Million TWD | -5.83% |
2022 | 949.2 Million TWD | 33.27% |
2021 | 712.23 Million TWD | -3.35% |
2020 | 736.92 Million TWD | 2.9% |
2019 | 716.17 Million TWD | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q3 | 193.62 Million TWD | -13.19% |
2024 Q1 | 222.38 Million TWD | 8.56% |
2024 Q2 | 223.04 Million TWD | 0.3% |
2023 Q3 | 207.24 Million TWD | -11.03% |
2023 Q4 | 204.86 Million TWD | -1.15% |
2023 Q2 | 232.93 Million TWD | -6.37% |
2023 Q1 | 248.79 Million TWD | -15.75% |
2022 Q4 | 295.32 Million TWD | 0.0% |
2022 FY | 949.2 Million TWD | 33.27% |
2021 FY | 712.23 Million TWD | -3.35% |
2020 FY | 736.92 Million TWD | 2.9% |
2019 FY | 716.17 Million TWD | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
BIONET Corp. | 1.12 Billion TWD | 20.71% |
Genetics Generation Advancement Corp. | 592.5 Million TWD | -50.86% |
Welgene Biotech Co.,Ltd. | 280.54 Million TWD | -218.608% |
Puriblood Medical Co., Ltd. | 125.26 Million TWD | -613.545% |
TFBS Bioscience Inc. | 231.91 Million TWD | -285.417% |